Who
Marc D. Beer
Executive Chairman
Company insider
Files Form 4 as: Executive Chairman, Biote; Director, Minerva Neurosciences; Chief Executive Officer, Aegerion Pharmaceuticals; President & CEO, Viacell.
In numbers
- Trades disclosed
- 107
- Buys
- 20
- Sells
- 3
- Bought
- $6.1M
- Sold
- $11.4M
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 7 Mar 2007
- Last trade
- 11 Aug 2026
- Last filed
- 12 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Aug 2026filed 12 Aug 2026 | BTMD BiotePharmaceuticals | SEC FORM 4 Bought | $25K16,000 at $1.55 | filing |
| 11 Aug 2026filed 12 Aug 2026 | BTMD BiotePharmaceuticals | SEC FORM 4 Bought | $25K16,000 at $1.55 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BTMD BiotePharmaceuticals | SEC FORM 4 Bought | $177K115,950 at $1.53 | filing |
| 10 Aug 2026filed 12 Aug 2026 | BTMD BiotePharmaceuticals | SEC FORM 4 Bought | $177K115,950 at $1.53 | filing |
| 8 Jun 2026filed 10 Jun 2026 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —114,157 at $0.00 | filing |
| 8 Jun 2026filed 10 Jun 2026 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —114,157 at $0.00 | filing |
| 12 May 2026filed 13 May 2026 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 12 May 2026filed 13 May 2026 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —195,000 at $0.00 | filing |
| 1 Apr 2025filed 2 Apr 2025 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —495,600 at $0.00 | filing |
| 17 Mar 2025filed 18 Mar 2025 | BTMD BiotePharmaceuticals | SEC FORM 4 Bought | $417K107,794 at $3.87 | filing |
| 1 Apr 2024filed 3 Apr 2024 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —543,958 at $0.00 | filing |
| 17 May 2023filed 19 May 2023 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —317,163 at $0.00 | filing |
| 9 Jan 2023filed 10 Jan 2023 | BTMD BiotePharmaceuticals | SEC FORM 4 Sold | $2.6M865,384 at $3.00 | filing |
| 6 Jan 2023filed 10 Jan 2023 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code C | —865,384 at $0.00 | filing |
| 6 Jan 2023filed 10 Jan 2023 | BTMD BiotePharmaceuticals | SEC FORM 4 Code C | —865,384 at $0.00 | filing |
| 6 Jan 2023filed 10 Jan 2023 | BTMD BiotePharmaceuticals | SEC FORM 4 Code J | —865,384 at $0.00 | filing |
| 15 Nov 2022filed 18 Nov 2022 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —477,721 at $0.00 | filing |
| 15 Nov 2022filed 16 Nov 2022 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —477,721 at $0.00 | filing |
| 26 May 2022filed 19 Sep 2022 | BTMD Bioteoption or derivative · Pharmaceuticals | SEC FORM 4 Code J | —654,387 at $0.00 | filing |
| 26 May 2022filed 19 Sep 2022 | BTMD BiotePharmaceuticals | SEC FORM 4 Code J | —654,387 at $0.00 | filing |
News
Clover Health Investments (NASDAQ:CLOV) vs. biote (NASDAQ:BTMD) Financial AnalysisBTMD · themarketsdaily.com · 15 Oct 2026
0 headlines in the last 90 days name Marc D. Beer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.